A Phase 2/3 interventional study of Fx-1006A in Familial Amyloid Polyneuropathy and ATTR-PN, sponsored by Pfizer. Completed at 11 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-12-17.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Amyloid Neuropathies, Familial with a site in Portugal — 4 open to participants now, 5 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Portugal.
Among the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 2/3, and was the 2nd registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →4 of the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal are open now. Recruiting first, the newest first:
Eidos Therapeutics, a BridgeBio company · Sites in Portugal, United States, Argentina and 21 more countries
Ages 18–75
Leiden University Medical Center · Sites in Portugal, Belgium, Italy and 2 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in Portugal, United States, Brazil and 9 more countries
Alnylam Pharmaceuticals · Sites in Portugal, United States, France and 4 more countries
Women only
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9
First in 2007; this study’s year is marked. 1 started in 2008.
This study's enrollment of 86 is above the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 192 across the 10 interventional studies, 300 across the 3 observational. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to determine the long-term safety and tolerability of Fx-1006A as well as the effects of Fx-1006A on clinical outcomes in patients with ATTR-PN.
All patients who enroll in this extension study will receive once-daily oral 20 mg Fx-1006A for 12 months; therefore, patients randomized to placebo in Study Fx-005 will cross over to active drug (Fx-1006A 20 mg) during this study. However, patients and their families as well as clinical Investigators and their clinical site staff will remain blinded to the original Fx-005 treatment assignment. It is intended that there will be no interruption in study medication administration between the two studies. The majority of safety and clinical outcomes assessments will be identical to those evaluated in Study Fx-005. Additional assessments for this open-label extension study include 24-hour Holter monitoring and skin biopsy for IENF; patients will be required to provide written informed consent to participate in this open-label extension study prior to having these additional procedures performed.
The values obtained from procedures and evaluations conducted during the Month 18 visit of Study Fx-005 will be used as the Baseline values for this open-label extension study. The Baseline assessments of IENF and Holter monitoring may be conducted at either day of the Month 18 visit days of Study Fx-005, but prior to the first Fx-1006A dose in this open-label extension study. Clinic Visits will be conducted at Week 6 (± 2 days), and Month 3 (± 1 week), Month 6 (± 2 weeks), and Month 12 (± 2 weeks). Monthly telephone contacts (± 1 week of the scheduled date) will be made during months in which no investigative site visits are scheduled (Months 2, 4, 5, 7, 8, 9, 10, and 11) for assessment of adverse events and concomitant medications.
Neurological evaluation by NIS-LL will be performed at Months 6 and 12. The NIS-LL will be assessed by utilizing the average of two successive NIS-LL clinical assessment scores obtained at least 24 hours apart within a one week period for each study visit. A dedicated neurologist will be required to perform NIS-LL scoring across all time-points for each individual patient enrolled in the study.
Quality of life utilizing the Norfolk QOL-DN will be assessed at Months 6 and 12 (based on the total score as well as the five individual domains of the questionnaire).
QST (utilizing CASE IV), NCS, HRDB, mBMI, and echocardiography will be conducted at Months 6 and 12. Holter monitoring will be conducted at Baseline and Months 6 and 12. Biopsies for IENF will be obtained at Baseline only. Assessments of troponin I and NT-pro-BNP levels will be made at each study visit.
Blood samples for pharmacokinetic assessments (Fx-1006A concentrations as well as calculated steady-state parameters) and pharmacodynamic assessments (TTR stabilization) will be collected at Week 6 and Months 6 and 12.
Safety and tolerability will be assessed throughout the study. Vital signs, 12-lead ECG, blood and urine samples for clinical laboratory tests (serum chemistry, hematology, coagulation panel, urinalysis, and urine pregnancy testing), adverse events, and concomitant medications will be assessed at each study visit. Eye examinations (including fundal photography) will be conducted at Months 6 and 12. Abbreviated physical examinations will be conducted at Week 6, and Months 3 and 6, and a complete physical examination will be conducted at Month 12.
All patients will be contacted by telephone 30 days (± 1 week) after the last dose of study medication for assessment of adverse events and concomitant medications.
Patients who complete the Month 12 visit of this open-label study may be allowed to continue receiving Fx-1006A under a compassionate use program.
Patients who discontinue from the study at any time after enrollment (i.e., early termination) will have final safety assessments performed at the time of discontinuation. Any patient discontinuing after the Month 6 visit will have all safety and clinical outcomes assessments scheduled for the Month 12 visit performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and non-pregnant female patients meeting all of the following criteria are eligible for enrollment in this study:
Exclusion Criteria:
Patients meeting any of the exclusion criteria will not be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fx-1006A
Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6
Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.
Time frame: Month 6
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12
Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.
Time frame: Month 12
Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
Time frame: Baseline, Month 6
Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
Time frame: Baseline, Month 12
Change From Baseline in Neuropathy Impairment Score - Lower Limb (NIS-LL) Score at Month 6 and 12
NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.
Time frame: Baseline, Month 6, 12
Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6 and 12
Norfolk QOL-DN: 35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptoms present, 0=symptoms absent. Item 8-35:scored on 5-point Likert scale: 0=no problem,4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment,for each. Total score=-2 to138(higher score=worse QOL).
Time frame: Baseline, Month 6, 12
Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6 and 12
Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.
Time frame: Baseline, Month 6, 12
Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6 and 12
Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.
Time frame: Baseline, Month 6, 12
Change From Baseline in Modified Body Mass Index (mBMI) at Month 6 and 12
BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation. A progressive decline in mBMI indicated worsening of disease severity.
Time frame: Baseline, Month 6, 12
Change From Baseline in Troponin I Concentration at Week 6, Month 3, 6 and 12
Troponin I was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).
Time frame: Baseline, Week 6, Month 3, 6, 12
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 6, Month 3, 6 and 12
NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).
Time frame: Baseline, Week 6, Month 3, 6, 12
Intraepidermal Nerve Fiber (IENF) Density
IENF density was quantified in 3 millimeter (mm) immunostained skin punch biopsies containing epidermis and superficial dermis to evaluate the amount and morphological appearance of small diameter nerve fibers, both somatic and autonomic, in sensory neuropathies. It is used in diagnosing various neuropathic conditions.
Time frame: Baseline
Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
Time frame: Month 6, 12
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
An Adverse Event (AE) was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug, up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 30 days after last dose of study medication
Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to Grade 3
AE=any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. Treatment-emergent events=between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 30 days after last dose of study medication
Number of Participants With Clinically Significant Treatment-emergent Echocardiography (ECHO) Findings
Clinically significant ECHO findings included: LV posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.
Time frame: Baseline, Day 1 up to Month 12 (anytime on-treatment)
Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings
Clinically significant ECG findings included: corrected QT (QTc) \> 450 ms, QTc \>500 ms, change in QTc between 30 and 60 ms, change in QTc greater than or equal to 60 ms.
Time frame: Baseline, Day 1 up to Month 12 (anytime on-treatment)
Number of Participants With Clinically Significant Treatment-emergent Holter Monitor Findings
Clinically significant Holter monitor findings included: atrial fibrillation/flutter, atrial tachycardia, non-sustained ventricular tachycardia (\<30 beats), sustained ventricular tachycardia (\>= 30 beats), sinus pause (RR \>2.0 second, where RR=60/heart rate), ventricular premature contractions.
Time frame: Baseline, Day 1 up to Month 12 (anytime on-treatment)
Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Baseline up to Month 12
Participants who completed study FX-005 (NCT00409175), were eligible for the current study FX-006 (NCT00791492).
| Milestone | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Started | 45 | 41 |
| Treated | 44 | 41 |
| Completed | 39 | 38 |
| Not completed | 6 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Liver transplantation | 5 | 1 |
Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.
| percentage of participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 | 62.2 (44.8 to 77.5) | 68.8 (50.0 to 83.9) |
Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.
| percentage of participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12 | 54.5 (36.4 to 71.9) | 60.0 (40.6 to 77.3) |
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
| units on a scale | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline | 21.05 ± 21.88 | 38.09 ± 31.89 |
| Change at Month 6 | 0.03 ± 8.83 | -4.88 ± 15.29 |
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
| units on a scale | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12 | 2.25 ± 8.91 | -2.33 ± 15.66 |
NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.
| units on a scale | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=38,33) | 8.38 ± 13.23 | 17.50 ± 20.82 |
| Change at Month 6 (n=37,32) | 0.93 ± 3.65 | 1.89 ± 4.55 |
| Change at Month 12 (n=33,30) | 1.36 ± 4.77 | 1.60 ± 8.20 |
Norfolk QOL-DN: 35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptoms present, 0=symptoms absent. Item 8-35:scored on 5-point Likert scale: 0=no problem,4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment,for each. Total score=-2 to138(higher score=worse QOL).
| units on a scale | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline: physical functioning (n=38,33) | 9.45 ± 11.43 | 19.88 ± 17.44 |
| Baseline: ADLs (n=38,33) | 2.21 ± 4.38 | 3.48 ± 5.13 |
| Baseline: symptoms (n=38,33) | 5.34 ± 4.43 | 7.48 ± 5.48 |
| Baseline: small fiber neuropathy (n=38,33) | 2.50 ± 3.85 | 4.42 ± 4.23 |
| Baseline: autonomic neuropathy (n=38,33) | 1.55 ± 2.37 | 2.82 ± 3.12 |
| Change at Month 6: physical functioning (n=37,32) | 0.14 ± 4.08 | -3.00 ± 8.08 |
| Change at Month 6: ADLs (n=37,32) | -0.30 ± 1.45 | -0.59 ± 3.02 |
| Change at Month 6: symptoms (n=34,32) | 0.00 ± 3.18 | -0.75 ± 4.27 |
| Change at Month 6: small fiber neuropathy(n=37,32) | -0.14 ± 2.64 | -0.09 ± 2.32 |
| Change at Month 6: autonomic neuropathy (n=37,32) | 0.19 ± 1.33 | -0.44 ± 2.00 |
| Change at Month 12: physical functioning(n=32,30) | 1.84 ± 6.00 | -0.83 ± 9.62 |
| Change at Month 12: ADLs (n=32,30) | 0.13 ± 1.01 | -0.50 ± 3.35 |
| Change at Month 12: symptoms (n=32,30) | -0.66 ± 2.54 | -1.10 ± 3.32 |
| Change at Month 12:small fiber neuropathy(n=32,30) | 0.41 ± 2.87 | 0.40 ± 2.61 |
| Change at Month 12: autonomic neuropathy (n=32,30) | 0.53 ± 1.46 | -0.30 ± 1.66 |
Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.
| units on a scale | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=38,33) | 6.68 ± 8.51 | 10.06 ± 10.68 |
| Change at Month 6 (n=37,32) | -0.01 ± 2.99 | 1.38 ± 3.58 |
| Change at Month 12 (n=33,30) | 0.64 ± 3.23 | 1.48 ± 4.02 |
Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.
| units on a scale | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=38,33) | 4.78 ± 4.33 | 7.08 ± 4.39 |
| Change at Month 6 (n=36,32) | 0.43 ± 1.51 | 0.38 ± 1.08 |
| Change at Month 12 (n=32,30) | 0.59 ± 1.28 | 0.50 ± 1.48 |
BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation. A progressive decline in mBMI indicated worsening of disease severity.
| (kilogram/square meter)*(gram/liter) | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=38,33) | 23.94 ± 2.97 | 22.71 ± 5.15 |
| Change at Month 6 (n=37,32) | -0.13 ± 0.81 | 0.42 ± 1.14 |
| Change at Month 12 (n=33,30) | -0.12 ± 1.16 | 0.73 ± 1.45 |
Troponin I was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).
| nanogram/milliliter (ng/mL) | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=29,30) | 0.2 (0.2 to 0.5) | 0.2 (0.2 to 0.2) |
| Change at Week 6 (n=28,29) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.0) |
| Change at Month 3 (n=29,30) | 0.0 (-0.1 to 0.3) | 0.0 (0.0 to 0.7) |
| Change at Month 6 (n=29,30) | 0.0 (0.0 to 0.6) | 0.0 (0.0 to 0.1) |
| Change at Month 12 (n=26,28) | 0.0 (-0.3 to 0.4) | 0.0 (0.0 to 0.0) |
NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).
| picogram/milliliter (pg/mL) | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=33,34) | 41.0 (19.0 to 2879.0) | 75.0 (20.0 to 1127.0) |
| Change at Week 6 (n=33,33) | 6.0 (-650.0 to 525.0) | -1.0 (-292.0 to 97.0) |
| Change at Month 3 (n=33,34) | 11.0 (-52.0 to 1355.0) | 1.0 (-514.0 to 229.0) |
| Change at Month 6 (n=33,33) | 9.0 (-210.0 to 3878.0) | 0.0 (-473.0 to 170.0) |
| Change at Month 12 (n=30,29) | 15.0 (-104.0 to 3840.0) | -6.0 (-342.0 to 410.0) |
IENF density was quantified in 3 millimeter (mm) immunostained skin punch biopsies containing epidermis and superficial dermis to evaluate the amount and morphological appearance of small diameter nerve fibers, both somatic and autonomic, in sensory neuropathies. It is used in diagnosing various neuropathic conditions.
| fibers/mm | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Left distal leg | 8.2 ± 9.8 | 8.0 ± 9.2 |
| Left proximal thigh | 16.1 ± 12.6 | 15.3 ± 11.9 |
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
| percentage of participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Month 6 | 94 (81 to 99) | 97 (83 to 99) |
| Month 12 | 94 (80 to 99) | 93 (77 to 99) |
An Adverse Event (AE) was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug, up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) | 5 | 4 |
AE=any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. Treatment-emergent events=between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to Grade 3 | 6 | 4 |
Clinically significant ECHO findings included: LV posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.
| participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=38,34) | 23 | 18 |
| Anytime on-treatment (n=21,23) | 16 | 13 |
Clinically significant ECG findings included: corrected QT (QTc) \> 450 ms, QTc \>500 ms, change in QTc between 30 and 60 ms, change in QTc greater than or equal to 60 ms.
| participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=44,41) | 16 | 17 |
| Anytime on-treatment (n=28,24) | 6 | 6 |
Clinically significant Holter monitor findings included: atrial fibrillation/flutter, atrial tachycardia, non-sustained ventricular tachycardia (\<30 beats), sustained ventricular tachycardia (\>= 30 beats), sinus pause (RR \>2.0 second, where RR=60/heart rate), ventricular premature contractions.
| participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Baseline (n=44,41) | 20 | 21 |
| Anytime on-treatment (n=24,20) | 8 | 7 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| participants | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis-Tafamidis | — | 5/44 (11.4%) | 24/44 (54.5%) |
| Placebo-Tafamidis | — | 4/41 (9.8%) | 24/41 (58.5%) |
| Event | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| VomitingGastrointestinal disorders | 2/44 | 1/41 |
| AnaemiaBlood and lymphatic system disorders | 0/44 | 1/41 |
| NauseaGastrointestinal disorders | 1/44 | 1/41 |
| InfectionInfections and infestations | 0/44 | 1/41 |
| MeningitisInfections and infestations | 0/44 | 1/41 |
| OsteomyelitisInfections and infestations | 0/44 | 1/41 |
| Urinary tract infectionInfections and infestations | 0/44 | 1/41 |
| DehydrationMetabolism and nutrition disorders | 0/44 | 1/41 |
| HypersensitivityImmune system disorders | 1/44 | 0/41 |
| Catheter sepsisInfections and infestations | 1/44 | 0/41 |
| Event | Tafamidis-Tafamidis | Placebo-Tafamidis |
|---|---|---|
| InfluenzaInfections and infestations | 3/44 | 7/41 |
| Urinary tract infectionInfections and infestations | 5/44 | 6/41 |
| HeadacheNervous system disorders | 2/44 | 6/41 |
| AnxietyPsychiatric disorders | 1/44 | 5/41 |
| NasopharyngitisInfections and infestations | 5/44 | 3/41 |
| VomitingGastrointestinal disorders | 2/44 | 4/41 |
| Thermal burnInjury, poisoning and procedural complications | 4/44 | 4/41 |
| DiarrhoeaGastrointestinal disorders | 4/44 | 3/41 |
| Punctate keratitisEye disorders | 3/44 | 3/41 |
| Dry eyeEye disorders | 2/44 | 3/41 |
| Age Continuous(years) | Tafamidis-Tafamidis | Placebo-Tafamidis | Total |
|---|---|---|---|
| Mean | 41.3 ± 13.4 | 39.6 ± 13.2 | 40.4 ± 13.3 |
| Sex: Female, Male(Participants) | Tafamidis-Tafamidis | Placebo-Tafamidis | Total |
|---|---|---|---|
| Female | 24 | 23 | 47 |
| Male | 20 | 18 | 38 |
The record gives a start of Jul 2008, a primary completion of Aug 2008 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 4 years 4 months after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis
Amyloid Neuropathies, Familial →